GC Green Cross MS Obtains Export Approval for Rapid Diagnostic Kit Utilizing Nano Semiconductors

[Asia Economy Reporter Cho Hyun-ui] GC Green Cross MS announced on the 29th that it has received export approval from the Ministry of Food and Drug Safety for its novel coronavirus infection (COVID-19) point-of-care testing (POCT) fluorescent immunoassay antigen diagnostic kit, ‘GENEDIA Quantum COVID-19 Ag.’

This product is the world’s first COVID-19 antigen diagnostic kit utilizing a fluorescent substance called nanosemiconductor, capable of diagnosing infection status on-site within 20 minutes.

By using nanosemiconductors to recognize antigen-antibody binding reactions, it diagnoses COVID-19 with a high level of test sensitivity (positive confirmation rate). Additionally, by using fluorescent immunoassay equipment, it can provide accurate results regardless of the tester’s skill level compared to conventional antigen diagnostic kits.

GC Green Cross MS explained that this product combines rapidity and accuracy with price competitiveness compared to polymerase chain reaction (PCR) tests. Therefore, it is expected to have demand not only in regions with weak medical infrastructure but also in advanced countries where the spread of COVID-19 is intensifying.

Ahn Eun-eok, CEO of GC Green Cross MS, said, “Through this export approval, we have been able to establish an integrated platform related to COVID-19 diagnostics and devise export strategies tailored to the differing demands of each country,” adding, “We will be able to proceed more aggressively with exports to advanced countries such as the United States and Europe in the future.”

This content was produced with the assistance of AI translation services.